Njira Lugogo, CHEST 2021: Tezepelumab for the Treatment of Severe, Uncontrolled Asthma
It was a pleasure to meet with Professor Njira Lugogo (University of Michigan, Ann Arbor, MI, USA) to discuss the findings from the NAVIGATOR study, investigating tezepelumab in adults and adolescents with severe, uncontrolled asthma (NCT03347279).
The abstract ‘TEZEPELUMAB PRODUCES CLINICALLY MEANINGFUL RESPONSES ON PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM THE PHASE 3 NAVIGATOR STUDY‘ was presented at CHEST 2021, 17-20 October 2021.
- What did the NAVIGATOR study teach us about the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma? (0:12)
- Why was it considered important to perform a pre-specified analysis of patient-reported outcomes? (1:15)
- What were the findings of this analysis? (2:40)
Disclosures: Njira Lugogo received consulting fees for advisory board participation from Amgen, AstraZeneca, Genentech, GSK, Novartis, Regeneron, Sanofi, and Teva; honoraria for non-speakers bureau presentations from GSK and Astra Zeneca; and travel support from Astra Zeneca; her institution received research support from Amgen, AstraZeneca, Avillion, Gossamer Bio, Genentech, GSK, Regeneron, Sanofi, and Teva.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of CHEST 2021 (Virtual).
Share this Video
Related Videos In Asthma
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ronald Strauss, AAAAI 2023: Hot topics to explore in the field of respiratory medicine
touchRESPIRATORY were delighted to speak with a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), about the areas in the field of respiratory medicine that he is most looking forward to exploring in 2023. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!